Last reviewed · How we verify
A second dose with an 5 year interval
A booster vaccination dose administered 5 years after initial immunization to maintain or restore protective immunity.
A booster vaccination dose administered 5 years after initial immunization to maintain or restore protective immunity. Used for Booster vaccination (specific pathogen unknown).
At a glance
| Generic name | A second dose with an 5 year interval |
|---|---|
| Sponsor | Shanghai Municipal Center for Disease Control and Prevention |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
This represents a revaccination strategy where a second dose is given at a 5-year interval following the primary vaccination series. The mechanism involves re-stimulating the adaptive immune system to boost antibody titers and cellular immunity that may have waned over time, ensuring sustained protection against the target pathogen.
Approved indications
- Booster vaccination (specific pathogen unknown)
Common side effects
- Injection site reactions (pain, erythema, swelling)
- Systemic reactions (fever, fatigue, myalgia)
Key clinical trials
- A Non-randomised, Non-inferiority Comparative Study of Oral Actiskenan (Morphine Sulfate) Versus Intranasal Sufentanil in the Early Management of Severe Acute Pain in Emergency Departments.
- Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia (PHASE3)
- Korea Comirnaty Post-marketing Surveillance
- Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines (PHASE1, PHASE2)
- Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors (NA)
- Immunogenicity of the Inactivated EV71 Vaccine Combined With Hepatitis B and Group A Meningococcal Vaccine (PHASE4)
- Randomised Evaluation of COVID-19 Therapy (PHASE3)
- Prospective Monitoring of BNT162b2 Second Vaccination Booster Effects in Health Care Workers (HCW)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: